A recent pilot clinical trial assessed two novel CD70-specific single-domain antibody tracers, (68Ga)Ga-NOTA-RCCB3 and (68Ga)Ga-NOTA-RCCB6, revealing that (68Ga)Ga-NOTA-RCCB6 immuno-PET/CT effectively identifies metastasis and postoperative recurrence in ccRCC (53). This evidence concerns the gene CD70 and nonpapillary renal cell carcinoma.